Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class 1 to 3~* 18 years of age or older~* Scheduled for elective surgical procedure under general anesthesia requiring neuromuscular block with the use of rocuronium~* Scheduled for surgery in supine position~* Given written informed consent~Exclusion Criteria:~* Participants in whom a difficult intubation is expected due to anatomical malformations~* Participants known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction~* Participants known or suspected to have a (family) history of malignant hyperthermia~* Participants known or suspected to have an allergy to narcotics, muscle relaxants or other medications used during surgery~* Participants receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and magnesium~* Female participants who are pregnant or breast-feeding~* Females participants of childbearing potential not using an acceptable method of birth control \[condom or diaphragm with spermicide, vasectomized partner (\> 6 months), intrauterine device (IUD), abstinence\]~* Participants who had already participated in a Org 25969 trial including Protocol 19.4.305~* Participants who had participated in another clinical trial, not pre-approved by Organon, within 30 days of entering into Protocol 19.4.305

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants 18 to 64 years old (Type: EXPERIMENTAL): Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
- Participants 65 to 74 years old (Type: EXPERIMENTAL): Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
- Participants 75 years and older (Type: EXPERIMENTAL): Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.

Based on this trial design, predict the completion outcome and termination type (if applicable).